(Q45353212)

English

Two-year results of reduced-fluence photodynamic therapy combined with intravitreal ranibizumab for typical age-related macular degeneration and polypoidal choroidal vasculopathy

scientific article published on 15 February 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Two-year results of reduced-fluence photodynamic therapy combined with intravitreal ranibizumab for typical age-related macular degeneration and polypoidal choroidal vasculopathy (English)

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

macular degeneration

1 reference

based on heuristic

inferred from title

author name string

Yusaku Yoshida

1

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Takeya Kohno

2

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Manabu Yamamoto

3

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Tasuku Yoneda

4

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Hisashi Iwami

5

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Kunihiko Shiraki

6

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

publication date

15 February 2013

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Japanese Journal of Ophthalmology

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

57

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

283-293

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Ranibizumab for neovascular age-related macular degeneration

1 reference

https://api.crossref.org/works/10.1007%2FS10384-013-0234-Z

21 January 2018

Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study

1 reference

https://api.crossref.org/works/10.1007%2FS10384-013-0234-Z

21 January 2018

A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study

1 reference

https://api.crossref.org/works/10.1007%2FS10384-013-0234-Z

21 January 2018

Intravitreal bevacizumab (Avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IBeVe Study).

1 reference

https://api.crossref.org/works/10.1007%2FS10384-013-0234-Z

21 January 2018

Combined intravitreal bevacizumab and photodynamic therapy for neovascular age-related macular degeneration

1 reference

https://api.crossref.org/works/10.1007%2FS10384-013-0234-Z

21 January 2018

Intravitreal injection of bevacizumab combined with verteporfin photodynamic therapy for choroidal neovascularization in age-related macular degeneration

1 reference

https://api.crossref.org/works/10.1007%2FS10384-013-0234-Z

21 January 2018

Verteporfin photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration

1 reference

https://api.crossref.org/works/10.1007%2FS10384-013-0234-Z

21 January 2018

Photodynamic therapy alone versus combined with intravitreal bevacizumab for neovascular age-related macular degeneration without polypoidal choroidal vasculopathy in Japanese patients

1 reference

https://api.crossref.org/works/10.1007%2FS10384-013-0234-Z

21 January 2018

Treatment of neovascular age-related macular degeneration with a variable ranibizumab dosing regimen and one-time reduced-fluence photodynamic therapy: the TORPEDO trial at 2 years

1 reference

https://api.crossref.org/works/10.1007%2FS10384-013-0234-Z

21 January 2018

Intravitreal bevacizumab alone versus in combination with photodynamic therapy for the treatment of neovascular maculopathy in patients aged 50 years or older: 1-year results of a prospective clinical study.

1 reference

https://api.crossref.org/works/10.1007%2FS10384-013-0234-Z

21 January 2018

Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor

1 reference

https://api.crossref.org/works/10.1007%2FS10384-013-0234-Z

21 January 2018

Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1007%2FS10384-013-0234-Z

21 January 2018

Low fluence rate photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration

1 reference

https://api.crossref.org/works/10.1007%2FS10384-013-0234-Z

21 January 2018

Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy: one-year results of a prospective case series.

1 reference

https://api.crossref.org/works/10.1007%2FS10384-013-0234-Z

21 January 2018

EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy.

1 reference

https://api.crossref.org/works/10.1007%2FS10384-013-0234-Z

21 January 2018

Hemorrhagic complications after photodynamic therapy for polypoidal choroidal vasculopathy

1 reference

https://api.crossref.org/works/10.1007%2FS10384-013-0234-Z

21 January 2018

One-year results of reduced-fluence photodynamic therapy for polypoidal choroidal vasculopathy

1 reference

https://api.crossref.org/works/10.1007%2FS10384-013-0234-Z

21 January 2018

Two-year results of photodynamic therapy for polypoidal choroidal vasculopathy.

1 reference

https://api.crossref.org/works/10.1007%2FS10384-013-0234-Z

21 January 2018

Recurrence of polypoidal choroidal vasculopathy after photodynamic therapy

1 reference

https://api.crossref.org/works/10.1007%2FS10384-013-0234-Z

21 January 2018

Three-year follow-up results of photodynamic therapy for polypoidal choroidal vasculopathy.

1 reference

https://api.crossref.org/works/10.1007%2FS10384-013-0234-Z

21 January 2018

Comparison of different treatment intervals between bevacizumab injection and photodynamic therapy in combined therapy for age-related macular degeneration.

1 reference

https://api.crossref.org/works/10.1007%2FS10384-013-0234-Z

21 January 2018

Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for polypoidal choroidal vasculopathy

1 reference

https://api.crossref.org/works/10.1007%2FS10384-013-0234-Z

21 January 2018

Efficacy of intravitreal bevacizumab combined with photodynamic therapy for polypoidal choroidal vasculopathy

1 reference

https://api.crossref.org/works/10.1007%2FS10384-013-0234-Z

21 January 2018

Photodynamic therapy combined with ranibizumab for polypoidal choroidal vasculopathy: results of a 1-year preliminary study

1 reference

https://api.crossref.org/works/10.1007%2FS10384-013-0234-Z

21 January 2018

One-year results of intravitreal ranibizumab with or without photodynamic therapy for polypoidal choroidal vasculopathy

1 reference

https://api.crossref.org/works/10.1007%2FS10384-013-0234-Z

21 January 2018

Two-year results of photodynamic therapy combined with intravitreal anti-vascular endothelial growth factor for polypoidal choroidal vasculopathy.

1 reference

https://api.crossref.org/works/10.1007%2FS10384-013-0234-Z

21 January 2018

Treatment of polypoidal choroidal vasculopathy with photodynamic therapy combined with intravitreal injections of ranibizumab

1 reference

https://api.crossref.org/works/10.1007%2FS10384-013-0234-Z

21 January 2018

Reduced-fluence photodynamic therapy combined with intravitreal bevacizumab for polypoidal choroidal vasculopathy.

1 reference

https://api.crossref.org/works/10.1007%2FS10384-013-0234-Z

21 January 2018

Bevacizumab for serous changes originating from a persistent branching vascular network following photodynamic therapy for polypoidal choroidal vasculopathy.

1 reference

https://api.crossref.org/works/10.1007%2FS10384-013-0234-Z

21 January 2018

Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration

1 reference

https://pubmed.ncbi.nlm.nih.gov/23413039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone

1 reference

https://pubmed.ncbi.nlm.nih.gov/23413039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Photodynamic effects on choroidal neovascularization and physiological choroid

1 reference

https://pubmed.ncbi.nlm.nih.gov/23413039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month results of the DENALI study

1 reference

https://pubmed.ncbi.nlm.nih.gov/23413039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration

1 reference

https://pubmed.ncbi.nlm.nih.gov/23413039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study

1 reference

https://pubmed.ncbi.nlm.nih.gov/23413039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Single-session photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration

1 reference

https://pubmed.ncbi.nlm.nih.gov/23413039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month MONT BLANC study results

1 reference

https://pubmed.ncbi.nlm.nih.gov/23413039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomised trial of bevacizumab and reduced light dose photodynamic therapy in age-related macular degeneration: the VIA study

1 reference

https://pubmed.ncbi.nlm.nih.gov/23413039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10384-013-0234-Z

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45353212&oldid=2207220994"